Primary Navigation for the CDC Web Site
CDC en Español
Prostate Cancer
divider
E-Mail Icon E-mail this page
Printer Friendly Icon Printer-friendly version
divider
 View by Topic
bullet Basic Information
bullet Statistics
bullet What CDC is Doing
bullet Informed Decision Making
bullet Publications
bullet Screening Decision Guide
bullet Screening Decision Guide for African Americans
bullet Sharing the Decision Slide Set
bullet Partners

Contact Information Centers for Disease
Control and Prevention
Division of Cancer
Prevention and Control
4770 Buford Hwy, NE
MS K-64
Atlanta, GA 30341-3717

Call: 1 (800) CDC-INFO
TTY: 1 (888) 232-6348
FAX: (770) 488-4760

E-mail: cdcinfo@cdc.gov

Submit a Question Online

Sharing the Decision Slide Set: Slide 7

Talking Points and Text Description of Slide

Previous Slide Index View Thumbnail View Next Slide
Slide 7
Previous Slide Index View Thumbnail View Next Slide

Slide 7 — Prostate Cancer Trends in Incidence and Mortality, 1973–1999

Talking Points

The risk of dying from or being diagnosed with prostate cancer has changed over time.

Let's look first at incidence—the rate of new cases—as shown by the top line. Note the general upward trend for detecting new prostate cancers—a substantial increase in the late 1980s, a peak around 1992, and a decline to a lower level.

The principal explanation for the dramatic increase in incidence in the late 1980s is that screening with PSA began to be adopted into usual practice. The steep rise was related to rapid and widespread dissemination of PSA test use for screening among men who had never been previously tested. A large pool of undetected prostate cancers was prevalent among those men. The peak was followed by a steep decline as the prevalent cancers in those men were detected.

Despite the decline from their peak, incidence rates in the mid and late 1990s remained higher than before the introduction of PSA testing. Continuing high rates could be due, in part, to the fact that some men had never had a PSA test and first-time PSA use among them was still finding prevalent cancers. Alternatively, the high rates may reflect, in part, the identification by PSA of cancers that otherwise would never have been detected. The latter issue, overdiagnosis of prostate cancer, is addressed later in the presentation.

As shown in the bottom line, mortality has changed but not as dramatically as incidence. We examine mortality rates in more detail later.

Sources: Ries et al., 2002; Etzioni et al., 2002; Potosky et al., 1995.

Text Description of Slide

Graph shows the trend of prostate cancer incidence and mortality rates from 1973 to 1990.

Page last reviewed: September 26, 2006
Page last updated: September 26, 2006
Content source: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
Safer, Healthier People

Centers for Disease Control and Prevention
1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov
USA.govDHHS Department of Health
and Human Services